UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 2, 2022
CARDIOVASCULAR SYSTEMS, INC.
(Exact name of Registrant as Specified in its Charter)

Delaware		000-52082		41-1698056	
(State or Other Jurisdiction
of Incorporation)		(Commission
File Number)		(IRS Employer
Identification No.)	

1225 Old Highway 8 Northwest
St. Paul, Minnesota 55112-6416
(Address of Principal Executive Offices and Zip Code)

651 259-1600
(Registrant’s telephone number, including area code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
						
☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)	

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)	

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))	

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))	

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (CFR 17 §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
									
Title of each class	Trading Symbol	Name of each exchange on which registered	
Common Stock, One-tenth of One Cent ($0.001)
Par Value Per Share	CSII	The Nasdaq Stock Market LLC	

Item 2.02.    Results of Operations and Financial Condition.

On August 2, 2022, Cardiovascular Systems, Inc. (the “Company”) issued a press release regarding the Company’s financial results for its fourth fiscal quarter and full year ended June 30, 2022, and posted on its website its Q4 FY22 Earnings Supplement Presentation, which contains certain additional historical and forward-looking information relating to the Company. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and a copy of the presentation is attached hereto as Exhibit 99.2.

Item 9.01.    Financial Statements and Exhibits.
						
(d)	Exhibits	

Exhibit
Number		Description	
		
99.1		Press Release dated August 2, 2022	
				
99.2			Q4 FY22 Earnings Supplement Presentation	

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 2, 2022

			
CARDIOVASCULAR SYSTEMS, INC.
 	
By:	 	/s/ Jeffrey S. Points	
	 	Jeffrey S. Points
Chief Financial Officer	

Exhibit 99.1

CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2022
FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

Webcast Scheduled for Tomorrow, August 3, 2022, at 9:00 a.m. CT (10:00 a.m. ET)

•Revenues of $62.5 million increased 11% sequentially compared to third quarter this year and decreased 12% compared to fourth quarter last year
•Management provides fiscal 23 revenue guidance of $255 million to $265 million, representing 8% to 12% growth compared to fiscal 22
•Capital Markets Day on August 3 to highlight product development in large, high-growth markets

St. Paul, Minn., August 2, 2022 – Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with vascular and coronary artery disease, today reported financial results for its fourth quarter and full year, ended June 30, 2022.

Executive Commentary – Scott Ward, Chairman, President and CEO
“During Q4, we achieved strong sequential growth across all business segments with our U.S. peripheral and coronary atherectomy franchises growing 9% and 16% over prior quarter, respectively. International revenues grew 14% sequentially to $5 million.

“In addition, key operating statistics, like new accounts, new customers trained and new contracts, continue to demonstrate strong demand for our products and position us for continued momentum in fiscal 23.

“We also achieved our key product development milestones in the quarter. Following the first in human experiences with our Propel™ percutaneous ventricular assist device in March, we recently submitted the investigational device exemption for the early feasibility study, which we expect to start in Q3. We also remain on track to achieve the milestones for our thrombectomy devices, intravascular lithotripsy and Everolimus drug-coated balloons.

“With strong execution in R&D and a compelling rebound in sales we have renewed momentum in our business and we are excited about the prospects for a strong year in fiscal 23.”

Fourth Quarter Financial Highlights
CSI’s fiscal 2022 fourth quarter revenues were $62.5 million, representing a decrease of $8.5 million, or 12.0% compared to the fourth quarter last year. Gross profit margin was 74.0%.

Selling, general and administrative expenses were $46.6 million, an increase of $0.9 million, or 1.9%. Research and development expenses decreased 5.1% to $8.8 million due to the timing of development activities.

Cardiovascular Systems, Inc.
August 2, 2022
Page 2
Fourth-quarter net loss of $9.7 million, or $0.25 per basic and diluted share, compared unfavorably to a loss of $5.3 million, or $0.14 per basic and diluted share, in the prior year period. The Adjusted EBITDA loss increased to $4.3 million from near breakeven in the prior year.

Fiscal Year 2022 Financial Highlights
CSI’s fiscal year 2022 revenues were $236.2 million, representing a decrease of $22.8 million, or 8.8%. Gross profit margin for the full year was 73.1%.

Selling, general and administrative expenses were $170.5 million, an increase of $3.0 million, or 1.8%, compared to the year ended June 30, 2021 as a result of increased field sales activities, customer education programs and medical conferences. Research and development expenses of $36.7 million decreased $4.3 million, or 10.6%, due to in process research and development (IPR&D) charges from the acquisition of a product portfolio of peripheral microcatheters for $3.4 million in the prior-year period.

Net loss of $36.9 million, or $0.94 per basic and diluted share, compared unfavorably to net loss of $13.4 million, or $0.35 per basic and diluted share, in the prior-year period. Adjusted EBITDA was $(12.9) million, as compared to $8.6 million in the prior year.

As of June 30, 2022, CSI had cash and marketable securities totaling $159.8 million and no long-term borrowings.

Fiscal Year 2023 Guidance
Ward added, “Our guidance anticipates attractive revenue growth in fiscal 23 with a gradual improvement in the state of the U.S. healthcare system combined with strong sales execution, accelerating revenue from the sale of interventional support devices, successful new product introductions and international expansion. Guidance assumes no new Covid headwinds, a gradual improvement in US hospital staffing shortages and the full resolution of the imaging contrast shortage in September."

For the fiscal year ending June 30, 2023, CSI anticipates:
•Revenue of $255 million to $265 million;
•Gross profit as a percentage of approximately 72% to 74% of revenues;
•Research and development expenses will be approximately 16% to 17% of revenues;
•Net loss in a range of 9% to 11% of revenues; and
•Adjusted EBITDA near break-even.

Webcast Scheduled for Tomorrow at 9:00 a.m. CT (10:00 a.m. ET)
In lieu of hosting a quarterly earnings call, CSI management will discuss fourth-quarter results at the beginning of its Capital Markets Day on August 3, 2022, at 9:00 a.m. CT (10:00 a.m. ET). To access the live webcast click here. A webcast replay will be available later the same day.

About Coronary Artery Disease (CAD)
CAD is a life-threatening condition and a leading cause of death in men and women globally. CAD occurs when a fatty material called plaque builds up on the walls of arteries that supply blood to the heart. The plaque buildup causes the arteries to harden and narrow (atherosclerosis), reducing blood flow. The risk of CAD increases if a person has one or more of the following: high blood pressure, abnormal cholesterol levels, diabetes, or family history of early heart disease. According to the Centers for Disease Control and Prevention, 18 million people in the United States have CAD, the most common form of heart disease. Heart disease claims more than 650,000 lives in the United States each year. According to estimates, arterial calcium is present in 38 percent of patients undergoing a PCI. Significant calcium contributes to poor stent delivery, expansion and wall apposition leading to poor outcomes and higher treatment costs in coronary interventions when traditional therapies are used, including a significantly higher occurrence of death and major adverse cardiac events (MACE).

Cardiovascular Systems, Inc.
August 2, 2022
Page 3
About Peripheral Artery Disease (PAD)
Eighteen to 20 million Americans, most over age 65, suffer from PAD, which is caused by the accumulation of plaque in peripheral arteries reducing blood flow. Symptoms include leg pain when walking or at rest. Left untreated, PAD can lead to severe pain, immobility, non-healing wounds and eventually limb amputation. With risk factors such as diabetes and obesity on the rise, the prevalence of PAD is growing at double-digit rates.

About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company’s orbital atherectomy system treats calcified and fibrotic plaque in arterial vessels throughout the leg and heart and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. For more information, visit www.csi360.com and follow us on LinkedIn and Twitter.

Safe Harbor
Certain statements in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statements in this press release regarding (i) CSI’s strategy, goals and prospects; (ii) the ongoing COVID-19 pandemic, its potential impact on our business, including trends in procedure volumes, the effects on the healthcare system, staffing shortages, patients returning for interventions, and case backlogs; (iii) expansion of our product portfolio and milestones relating thereto, including the specific products, clinical trials and experiences, and timing thereof, and the benefits to CSI; (iv) our expectations regarding attractive revenue growth, improvement in the state of the U.S. healthcare system, sales execution, accelerating revenue from the sale of interventional support devices, successful new product introductions, international expansion, Covid headwinds, staffing shortages and the resolution of the imaging contrast shortage; and (v) anticipated revenue, gross profit, research and development expenses, net loss and Adjusted EBITDA, are forward-looking statements. These statements involve risks and uncertainties that could cause results to differ materially from those projected, including, but not limited to, the ongoing COVID-19 pandemic and the impact and scope thereof on CSI, our distribution partners, the supply chain and physicians and facilities, including government actions related to the COVID-19 outbreak, material delays and cancellations of procedures, delayed spending by healthcare providers, and distributor and supply chain disruptions; regulatory developments, clearances and approvals; approval of our products for distribution in countries outside of the United States; approval of products for reimbursement and the level of reimbursement in the U.S. and other countries; dependence on market growth; agreements with third parties to sell their products; the ability of us and our distribution partners to successfully launch CSI products outside of the United States; our ability to maintain third-party supplier relationships and renew existing purchase agreements; our ability to maintain our relationships with our distribution partners; the experience of physicians regarding the effectiveness and reliability of the products we sell; the reluctance of physicians, hospitals and other organizations to accept new products; the potential for unanticipated delays in enrolling medical centers and patients for clinical trials; actual clinical trial and study results; the impact of competitive products and pricing; unanticipated developments affecting our estimates regarding expenses, future revenues and capital requirements; the difficulty of successfully managing operating costs; our ability to manage our sales force strategy; our actual research and development efforts and needs, including the timing of product development programs; successful collaboration on the development of new products; agreements with development partners, advisors and other third parties; the ability of CSI and these third parties to meet development, contractual and other milestones; contractual rights and obligations; technical challenges; our ability to obtain and maintain intellectual property protection for product candidates; our actual financial resources and our ability to obtain additional financing; fluctuations in results and expenses based on new product introductions, sales mix, unanticipated warranty claims, and the timing of project expenditures; our ability to manage costs; investigations or litigation threatened or initiated against us; court rulings and future actions by the FDA and other regulatory bodies; the effects of hurricanes, flooding, and other natural disasters on our business; the impact of federal corporate tax reform on our business, operations and financial statements; international trade developments; shutdowns of the U.S. federal government; general economic

Cardiovascular Systems, Inc.
August 2, 2022
Page 4
conditions; the potential impact of any future strategic transactions; and other factors detailed from time to time in CSI’s SEC reports, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. CSI encourages you to consider all of these risks, uncertainties and other factors carefully in evaluating the forward-looking statements contained in this release. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, CSI's actual results may differ materially from the expected results discussed in the forward-looking statements contained in this release. The forward-looking statements made in this release are made only as of the date of this release, and CSI undertakes no obligation to update them to reflect subsequent events or circumstances.

Cardiovascular Systems, Inc.
August 2, 2022
Page 5
Product Disclosures:
Peripheral Products
Indications: The Stealth 360® PAD System and Diamondback 360® PAD System are percutaneous orbital atherectomy systems (OAS) indicated for use as therapy in patients with occlusive atherosclerotic disease in peripheral arteries and stenotic material from artificial arteriovenous dialysis fistulae.

Contraindications: The OAS are contraindicated for use in coronary arteries, bypass grafts, stents or where thrombus or dissections are present.

Warnings/Precautions: Although the incidence of adverse events is rare, potential events that can occur with atherectomy include: pain, hypotension, CVA/TIA, death, dissection, perforation, distal embolization, thrombus formation, hematuria, abrupt or acute vessel closure, or arterial spasm.

See the instructions for use for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential adverse events. For further information call CSI at 1-877-274-0901 and/or consult CSI’s website at www.csi360.com.

Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician.

The Stealth 360® PAD System and Diamondback 360® PAD System received FDA 510(k) clearance. The Stealth 360® PAD System is CE Marked.

Coronary Product
Indications: The Diamondback 360® Coronary Orbital Atherectomy System (OAS) is a percutaneous orbital atherectomy system indicated to facilitate stent delivery in patients with coronary artery disease (CAD) who are acceptable candidates for PTCA or stenting due to de novo, severely calcified coronary artery lesions.

Contraindications: The OAS is contraindicated when the ViperWire® guide wire cannot pass across the coronary lesion or the target lesion is within a bypass graft or stent. The OAS is contraindicated when the patient is not an appropriate candidate for bypass surgery, angioplasty, or atherectomy therapy, or has angiographic evidence of thrombus, or has only one open vessel, or has angiographic evidence of significant dissection at the treatment site and for women who are pregnant or children.

Warnings/Precautions: Performing treatment in excessively tortuous vessels or bifurcations may result in vessel damage; The OAS was only evaluated in severely calcified lesions, A temporary pacing lead may be necessary when treating lesions in the right coronary and circumflex arteries; On-site surgical back-up should be included as a clinical consideration; Use in patients with an ejection fraction (EF) of less than 25% has not been evaluated.

See the instructions for use for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential adverse events. For further information call CSI at 1-877-274-0901 and/or consult CSI’s website at www.csi360.com.

Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician.

The Diamondback 360® Coronary OAS is FDA PMA approved and CE Marked.

Cardiovascular Systems, Inc.
August 2, 2022
Page 6

Cardiovascular Systems, Inc.
Consolidated Statements of Operations
(Dollars in Thousands)
(unaudited)

		Three Months Ended		Year Ended	
		June 30		June 30	
		2022		2021		2022		2021	
									
Net revenues		$	62,496 			$	70,987 			$	236,222 			$	258,973 		
Cost of goods sold		16,269 			20,634 			63,440 			61,131 		
Gross profit		46,227 			50,353 			172,782 			197,842 		
Expenses:									
Selling, general and administrative		46,593 			45,713 			170,526 			167,498 		
Research and development		8,773 			9,245 			36,720 			41,061 		
Amortization of intangible assets		346 			304 			1,342 			1,216 		
Total expenses		55,712 			55,262 			208,588 			209,775 		
Loss from operations		(9,485)			(4,909)			(35,806)			(11,933)		
Other (income) expense, net		157 			313 			817 			1,236 		
Loss before income taxes		(9,642)			(5,222)			(36,623)			(13,169)		
Provision for income taxes		48 			63 			310 			252 		
Net loss		$	(9,690)			$	(5,285)			$	(36,933)			$	(13,421)		
									
Basic and diluted earnings per share		$	(0.25)			$	(0.14)			$	(0.94)			$	(0.35)		

Basic and diluted weighted average shares outstanding		39,346,771 			38,926,490 			39,229,734 			38,832,002 		

Cardiovascular Systems, Inc.
August 2, 2022
Page 7
Cardiovascular Systems, Inc.
Consolidated Balance Sheets
(Dollars in Thousands)
(unaudited)
												
	June 30,		June 30,	
	2022		2021	
				
ASSETS				
Current assets				
Cash and cash equivalents	$	66,424 			$	71,070 		
Marketable securities	93,409 			135,968 		
Accounts receivable, net	39,678 			40,033 		
Inventories	34,567 			32,313 		
Prepaid expenses and other current assets	7,768 			5,285 		
Total current assets	241,846 			284,669 		
Property and equipment, net	29,035 			28,894 		
Intangible assets, net	15,734 			15,376 		
Strategic investments	33,425 			20,657 		
Other assets	2,637 			2,971 		
Total assets	$	322,677 			$	352,567 		
				
LIABILITIES AND STOCKHOLDERS’ EQUITY				
Current liabilities				
Accounts payable	$	14,383 			$	14,061 		
Accrued expenses	23,464 			38,189 		
Deferred revenue	2,107 			2,400 		
Total current liabilities	39,954 			54,650 		
Long-term liabilities				
Financing obligation	20,298 			20,596 		
Deferred revenue	— 			2,194 		
Other liabilities	12,945 			4,169 		
Total liabilities	73,197 			81,609 		
Commitments and contingencies	— 			— 		
Total stockholders’ equity	249,480 			270,958 		
Total liabilities and stockholders’ equity	$	322,677 			$	352,567 		

Cardiovascular Systems, Inc.
August 2, 2022
Page 8

Non-GAAP Financial Measures
To supplement CSI's consolidated condensed financial statements prepared in accordance with GAAP, CSI uses a non-GAAP financial measure referred to as "Adjusted EBITDA" in this release.

Reconciliations of these non-GAAP measures to the most comparable U.S. GAAP measures for the respective periods can be found in the following tables. In addition, an explanation of the manner in which CSI's management uses these measures to conduct and evaluate its business, the economic substance behind management's decision to use these measures, the substantive reasons why management believes that these measures provide useful information to investors, the material limitations associated with the use of these measures and the manner in which management compensates for those limitations is included following the reconciliation tables.

Adjusted EBITDA
(Dollars in Thousands)
(unaudited)
																								
	Three Months Ended		Year Ended	
	June 30		June 30	
	2022		2021		2022		2021	
								
Net loss	$	(9,690)			$	(5,285)			$	(36,933)			$	(13,421)		
Less: Other (income) and expense, net	157 			313 			817 			1,236 		
Less: Provision for income taxes	48 			63 			310 			252 		
Loss from operations	(9,485)			(4,909)			(35,806)			(11,933)		
Add: Stock-based compensation	4,037 			3,742 			17,841 			16,230 		
Add: Depreciation and amortization	1,198 			1,169 			5,029 			4,312 		
Adjusted EBITDA	$	(4,250)			$	2 			$	(12,936)			$	8,609 		

Use and Economic Substance of Non-GAAP Financial Measures Used by CSI and Usefulness of Such Non-GAAP Financial Measures to Investors
CSI uses Adjusted EBITDA as a supplemental measure of performance and believes this measure facilitates operating performance comparisons from period to period and company to company by factoring out potential differences caused by depreciation and amortization expense and stock-based compensation. CSI's management uses Adjusted EBITDA to analyze the underlying trends in CSI's business, assess the performance of CSI's core operations, establish operational goals and forecasts that are used to allocate resources and evaluate CSI's performance period over period and in relation to its competitors' operating results. Additionally, CSI's management is evaluated on the basis of Adjusted EBITDA when determining achievement of their incentive compensation performance targets.

CSI believes that presenting Adjusted EBITDA provides investors greater transparency to the information used by CSI's management for its financial and operational decision-making and allows investors to see CSI's results "through the eyes" of management. CSI also believes that providing this information better enables CSI's investors to understand CSI's operating performance and evaluate the methodology used by CSI's management to evaluate and measure such performance.

The following is an explanation of each of the items that management excluded from Adjusted EBITDA and the reasons for excluding each of these individual items:

Cardiovascular Systems, Inc.
August 2, 2022
Page 9
-- Stock-based compensation. CSI excludes stock-based compensation expense from its non-GAAP financial measures primarily because such expense, while constituting an ongoing and recurring
expense, is not an expense that requires cash settlement. CSI's management also believes that excluding this item from CSI's non-GAAP results is useful to investors to understand the application of stock-based compensation guidance and its impact on CSI's operational performance, liquidity and its ability to make additional investments in the company, and it allows for greater transparency to certain line items in CSI's financial statements.

-- Depreciation and amortization expense. CSI excludes depreciation and amortization expense from its non-GAAP financial measures primarily because such expenses, while constituting ongoing and recurring expenses, are not expenses that require cash settlement and are not used by CSI's management to assess the core profitability of CSI's business operations. CSI's management also believes that excluding these items from CSI's non-GAAP results is useful to investors to understand CSI's operational performance, liquidity and its ability to make additional investments in the company.

Beginning with the quarter ended March 31, 2022, following correspondence from the staff of the U.S. Securities and Exchange Commission, we no longer exclude IPR&D charges incurred in connection with asset acquisitions from Adjusted EBITDA or any other reported non-GAAP financial measures. For purposes of comparability, we have revised the reconciliation table above for the three and twelve months ended June 30, 2021 to reflect this approach.

Material Limitations Associated with the Use of Non-GAAP Financial Measures and Manner in which CSI Compensates for these Limitations
Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for CSI's financial results prepared in accordance with GAAP. Some of the limitations associated with CSI's use of these non-GAAP financial measures are:
-- Items such as stock-based compensation do not directly affect CSI's cash flow position; however, such items reflect economic costs to CSI and are not reflected in CSI's "Adjusted EBITDA" and therefore these non-GAAP measures do not reflect the full economic effect of these items.

-- Non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles and therefore other companies may calculate similarly titled non-GAAP financial measures differently than CSI, limiting the usefulness of those measures for comparative purposes.

-- CSI's management exercises judgment in determining which types of charges or other items should be excluded from the non-GAAP financial measures CSI uses. CSI compensates for these limitations by relying primarily upon its GAAP results and using non-GAAP financial measures only supplementally. CSI provides full disclosure of each non-GAAP financial measure.

-- CSI provides detailed reconciliations of each non-GAAP measure to its most directly comparable GAAP measure. CSI encourages investors to review these reconciliations. CSI qualifies its use of non-GAAP financial measures with cautionary statements as set forth above.

Contact:
						
Cardiovascular Systems, Inc.
Jack Nielsen
Vice President, Investor Relations & Corporate Communications
(651) 202-4919
j.nielsen@csi360.com		
# # #

©2022 Cardiovascular Systems, Inc. All Rights Reserved. Q4 FY22 Earnings Supplement August 2, 2022

 

Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statements in this presentation regarding CSI’s strategy; goals; growth; future financial measurements; product development plans, milestones and introductions; geographic expansion; reimbursement expectations; distributed products; clinical trials and evidence; future investments and financing needs; market estimates and opportunities; and developments related to the COVID-19 pandemic; are forward-looking statements. These statements involve risks and uncertainties that could cause results differ materially from those projected, including, but not limited to, those described in CSI’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly and annual reports. CSI encourages you to consider all of these risks, uncertainties and other factors carefully in evaluating the forward-looking statements contained in this presentation. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, CSI’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this presentation. The forward- looking statements contained in this presentation are made only as of the date of this presentation, and CSI undertakes no obligation to update them to reflect subsequent events or circumstances. 2 FORWARD LOOKING STATEMENTS FINANCIAL INFORMATION This presentation includes calculations or figures that have been prepared internally and have not been reviewed or audited by CSI’s independent registered accounting firm. Use of different methods for preparing, calculating or presenting information may lead to differences, which may be material. In addition, this presentation also includes certain non-GAAP financial measures, such as Adjusted EBITDA. Reconciliations of the non-GAAP financial measures used in this presentation to the most comparable U.S. GAAP measures for the respective periods can be found in tables in the appendix to this presentation. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for CSI's financial results prepared in accordance with GAAP.

 

11.2% increase Q/Q and 12.0% decrease Y/Y Q4 FY22 Worldwide Revenues of $62.5 Million Q4 FY22 Revenue Breakdown Worldwide Peripheral $40.7 9.0% Q/Q -14.7% Y/Y Worldwide Coronary $21.8 15.5% Q/Q -6.3% Y/Y Worldwide Peripheral Worldwide Coronary ($ in millions, Q/Q and Y/Y represent Quarter-over-Quarter and Year-over-Year growth rates) • Strong sequential revenue growth in all three business segments • U.S. Coronary increased 15.8% vs. Q3 • U.S. Peripheral increased 8.9% vs. Q3 • International increased 14.4% vs. Q3 • Hospital staffing shortages and the transient shortage of imaging contrast media in some regions may have constrained hospital procedure volumes particularly for lower acuity patients. • Net loss of ($9.7M) compared to ($5.3M) in the year ago period • Cash and cash equivalents of $159.8M as of June 30, 2022 • Proposed atherectomy reimbursement changes for CY23 result in an estimated 2.7% increase in coronary procedures and an estimated 0.4% increase in peripheral procedures. Q4 FY22 Highlights 3

 

Q4 FY22: U.S. Peripheral 1 Is the total of Orbital Atherectomy System Revenue plus Interventional Support Device Revenue 2 Includes peripheral orbital atherectomy devices, ViperWire, ViperSlide, Exchangeable cartridges, ViperTrack and other 3 Zilient Guidewires, JADE angioplasty balloons, ViperCath and WIRION 4 Revenue increased 8.9% Q/Q and decreased 15.0% Y/Y • U.S. units increased 17.1% Q/Q and decreased 11.6% Y/Y due to: • Stabilization of procedure volumes compared to Q3, but remained lower than the year ago period due primarily to hospital staffing and contrast shortages. Hospital units increased 0.6% Q/Q, but decreased 20.7% Y/Y • OBL units increased 35.1% Q/Q and decreased 2.6% Y/Y • Peripheral ISD revenue increased 35.7% Q/Q and 117.2% Y/Y to $1.8M, representing $110 of incremental revenue for every peripheral unit sold • Trained 40 new physicians and opened 52 new peripheral accounts • Received early approval for 2.0 Max crown for mixed plaque ATK. The full market release is scheduled for 2H FY23 U.S Peripheral Revenue1 ($ in 000) Q1 Q2 Q3 Q4 Total FY20 $45,272 $47,463 $42,134 $30,667 $165,536 FY21 $42,932 $43,924 $42,104 $47,648 $176,608 FY22 $38,878 $38,813 $37,158 $40,480 $155,329 Orbital Atherectomy System Revenue2 ($ in 000) Q1 Q2 Q3 Q4 Total FY20 $44,944 $47,159 $41,839 $30,465 $164,407 FY21 $42,657 $43,625 $41,782 $46,836 $174,900 FY22 $37,521 $37,640 $35,858 $38,716 $149,735 Interventional Support Device Revenue3 ($ in 000) Q1 Q2 Q3 Q4 Total FY20 $328 $304 $295 $202 $1,129 FY21 $275 $299 $322 $812 $1,708 FY22 $1,357 $1,173 $1,300 $1,764 $5,594 OBL volumes improving / Hospital volumes stabilizing

 

Q4 FY22: U.S. Coronary 1 Is the total of Orbital Atherectomy System Revenue plus Interventional Support Device Revenue 2 Includes Diamondback, Coronary Guidewire, ViperSlide and other 3 Includes Sapphire angioplasty balloons, Teleport microcatheters and Scoreflex NC balloons Coronary procedure volumes rebounding 5 Revenue increased 15.8% Q/Q and decreased 13.4% Y/Y • U.S. Coronary OAS units sold increased 11.4% Q/Q as volumes improved vs. Q3 and decreased 23.2% Y/Y as staffing and contrast shortages combined to reduce procedure volumes compared to the year ago period • Coronary ISD revenue increased 37.3% Q/Q and 37.6% Y/Y to $3.9M • Certified 39 new physicians and opened 13 new coronary accounts • ECLIPSE enrollment of 1,858 as of June 30, 2022 U.S Coronary Revenue1 ($ in 000) Q1 Q2 Q3 Q4 Total FY20 $16,257 $18,497 $15,988 $9,785 $60,527 FY21 $15,899 $17,983 $17,489 $19,645 $71,016 FY22 $16,164 $16,658 $14,685 $17,007 $64,514 Orbital Atherectomy System Revenue2 ($ in 000) Q1 Q2 Q3 Q4 Total FY20 $14,669 $16,490 $14,058 $8,651 $53,868 FY21 $13,952 $15,762 $15,093 $16,781 $61,588 FY22 $13,505 $13,927 $11,813 $13,065 $52,310 Interventional Support Device Revenue3 ($ in 000) Q1 Q2 Q3 Q4 Total FY20 $1,588 $2,007 $1,930 $1,134 $6,659 FY21 $1,947 $2,221 $2,396 $2,864 $9,428 FY22 $2,659 $2,731 $2,872 $3,942 $12,204

 

Q4 FY22: International Double-digit Q/Q and Y/Y revenue growth driven by Japan and EU coronary 6 Revenue increased 14.4% Q/Q and 35.6% Y/Y • International revenue increased to $5.0 million driven by: • Japan, where revenue increased 7.5% Q/Q and 14.2% Y/Y • Europe, where revenue increased 14.5% Q/Q and 34.3% Y/Y • Certified 78 new physicians • Opened 39 new accounts • Launched coronary in 16 new countries fiscal 22 • Plan to launch OAS in 15+ new countries in fiscal 23 ($ in 000) Q1 Q2 Q3 Q4 Total FY20 $2,961 $2,374 $3,053 $2,094 $10,482 FY21 $1,713 $2,262 $3,680 $3,694 $11,349 FY22 $3,328 $3,664 $4,378 $5,009 $16,379 Countries Launched in Q4 FY22 Country Coronary Chile Q4 FY22 Oman Q4 FY22 Bahrain Q4 FY22 30 countries OUS launched to date.

 

Q4 FY22 vs. Q3 FY22 and Q4 FY22 Dollars in thousands 7 Q4 FY22 Quarter/Quarter Change Year/Year Change Worldwide Revenue $62,496 11.2% -12.0% Worldwide Peripheral Revenue $40,729 9.0% -14.7% Worldwide Coronary Revenue $21,767 15.5% -6.3% U.S. Revenue $57,487 10.9% -14.6% U.S. Peripheral Revenue $40,480 8.9% -15.0% U.S. Coronary Revenue $17,007 15.8% -13.4% International Revenue $5,009 14.4% 35.6% U.S. Peripheral Units - 17.1% -11.6% U.S. Coronary Units - 11.4% -23.2%

 

Q4 FY22: Select Financial Information Dollars in thousands, except earnings per share and shares outstanding 8 Q4 FY22 Q3 FY22 Q/Q Change Fav (Unfav) Q4 FY21 Y/Y Change Fav (Unfav) Net revenues $62,496 $56,221 $6,275 $70,987 ($8,491) Cost of goods sold 16,269 14,790 (1,479) 20,634 4,365 Gross Margin 74.0% 73.7% Increased 30 BP 70.9% Increased 310 BP Selling, general and administrative 46,593 41,680 (4,913) 45,713 (880) % of sales 74.6% 74.1% Increased 50 BP 64.4% Increased 1020 BP Research and development 8,773 9,052 279 9,245 472 % of sales 14.0% 16.1% Decreased 210 BP 13.0% Increased 100 BP Amortization of intangible assets 346 346 - 304 (42) Loss from operations (9,485) (9,647) 162 (4,909) (4,576) Other (income) and expense, net 157 (52) (209) 313 156 Provision for income taxes 48 63 15 63 15 Net loss ($9,690) ($9,658) ($32) ($5,285) ($4,405) Basic and diluted earnings per share ($0.25) ($0.25) - ($0.14) ($0.11) Basic and diluted weighted average shares outstanding 39,346,771 39,287,632 59,139 38,926,490 420,281

 

FY23: Annual Guidance 9 For the fiscal year ending June 30, 2023, CSI anticipates: Revenue of $255 million to $265 million; Gross profit as a percentage of revenues of 72% to 74%; Net loss in a range of 9% to 11% of revenues; and Adjusted EBITDA near break-even. Research and development expenses will be approximately 16% to 17% of revenues;

 

Non-GAAP Financial Measures 10 CSI uses Adjusted EBITDA as a supplemental measure of performance and believes this measure facilitates operating performance comparisons from period to period and company to company by factoring out potential differences caused by depreciation and amortization expense and stock-based compensation. CSI's management uses Adjusted EBITDA to analyze the underlying trends in CSI's business, assess the performance of CSI's core operations, establish operational goals and forecasts that are used to allocate resources and evaluate CSI's performance period over period and in relation to its competitors' operating results. Additionally, CSI's management is evaluated on the basis of Adjusted EBITDA when determining achievement of their incentive compensation performance targets. Beginning with the quarter ended March 31, 2022, following correspondence from the staff of the U.S. Securities and Exchange Commission, we no longer exclude in process research and development (IPR&D) charges incurred in connection with asset acquisitions from Adjusted EBITDA or any other reported non-GAAP financial measures. For purposes of comparability, we have revised the reconciliation table above for the third quarter and full year of fiscal 2021. CSI believes that presenting Adjusted EBITDA provides investors greater transparency to the information used by CSI's management for its financial and operational decision-making and allows investors to see CSI's results "through the eyes" of management. CSI also believes that providing this information better enables CSI's investors to understand CSI's operating performance and evaluate the methodology used by CSI's management to evaluate and measure such performance. ($ in thousands) FY20 Q1 FY21 Q2 FY21 Q3 FY21 Q4 FY21 FY21 Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 FY22 Net loss ($27,236) ($2,076) ($56) ($6,004) ($5,285) ($13,421) ($8,618) ($8,967) ($9,658) ($9,690) ($36,933) Less: Other (income) and expense, net 233 355 276 292 313 1,236 367 345 (52) 157 817 Less: Provision for income taxes 231 63 63 63 63 252 136 63 63 48 310 Income (loss) from operations (26,772) (1,658) 283 (5,649) (4,909) (11,933) (8,115) (8,559) (9,647) (9,485) (35,806) Add: Stock-based compensation 13,612 4,907 3,877 3,704 3,742 16,230 5,672 4,240 3,892 4,037 17,841 Add: Depreciation and amortization 4,179 1,029 1,058 1,056 1,169 4,312 1,258 1,287 1,286 1,198 5,029 Adjusted EBITDA ($8,981) $4,278 $5,218 ($889) $2 $8,609 ($1,185) ($3,032) ($4,469) ($4,250) ($12,936) Use and Economic Substance of Non-GAAP Financial Measures Used by CSI and Usefulness of Such Non-GAAP Financial Measures to Investors

 

Investor Contact: Jack Nielsen Vice President, Investor Relations & Corporate Communications 651-202-4919 j.nielsen@csi360.com CSI®, Diamondback®, Diamondback 360®, ViperWire®, ViperWire Advance®, Wirion®, Zilient®, ViperTrack®, Propel™, ViperCath™ and ViperCross™ are trademarks of Cardiovascular Systems, Inc. OrbusNeich®, Sapphire®, Jade®, Teleport® and Scoreflex® are trademarks of OrbusNeich Medical, Inc. Cardiovascular Systems, Inc. CSII @csi360 11